Skip to content

comparison of 2 prostate intervention by surgery:- TURP and HOLEP.to see main outcome and perioperative complications

A comparative observational prospective study to assess outcome in monopolar transurethral resection of the prostate (turp) vs holmium laser enucleation of the prostate (holep) in benign prostatic hyperplasia - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/099812
Enrollment
68
Registered
2025-12-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: Nil: Nil

Sponsors

Bhaktivedanta Hospital and Research Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male patients age more than 50 years 2. Diagnosed with symptomatic BPH with moderate to severe lower urinary tract symptoms (International Prostate Symptom Score [IPSS] more than or equal to 8). 3. Patient of BPH with recurrent UTI and recurrent Hematuria. 4. Prostate size between 40 mL and 100 mL as assessed by prostate ultrasound done by Senior Radiologist at our hospital (Voluson). 5. Patients consenting to undergo surgical treatment and participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patients with prostate cancer confirmed by biopsy. 2. Patients with neurogenic bladder or other neurological conditions affecting voiding. 3. Previous prostate surgery. 4. Presence of active urinary tract infection. Patients unfit for anaesthesia or surgery.

Design outcomes

Primary

MeasureTime frame
Prostate weight in gm Hemoglobin drop(g/dL) postoperatively. Catheterization time (hours). Length of hospital stay (days). Perioperative complications (INCONTINENCE, RETENTION). S.PSA drop postoperatively Prostate weight in gm Operative time (minutes). Timepoint: 1 , 3 , 6 and 12 months

Secondary

MeasureTime frame
Improvement in International Prostate Symptom Score (IPSS) at 1, 3,6 and 12 months. Improvement in maximum urinary flow rate (Qmax) at 1, 3,6 and 12 months. Timepoint: 1 , 3 , 6 and 12 months

Countries

India

Contacts

Public ContactDr Harshad Kavad

Bhaktivedanta Hospital and Research Institute

drvikash.k@bhaktivedantahospital.com9820163302

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026